This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This protocol is designed to assess the immunogenicity of a vaccine consisting of five ovarian cancer-associated peptides in adjuvant in patients with Stage III or IV ovarian cancer. Secondary endpoints include assessment of the immunogenicity of the vaccine during and after chemotherapy, and cytotoxic T-cell responses against autologous and/or MHC-matched allogeneic tumor cells.
Showing the most recent 10 out of 674 publications